Antifungal Prescribing in European Pediatric Intensive Care Units: Results of a Multinational 3-Month Weekly Point-Prevalence Survey
Journal of the Pediatric Infectious Diseases Society · 2025
DOI: 10.1093/jpids/piaf081 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2025. Verfasst von Elisavet Chorafa und 27 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, 3rd Department of Pediatrics, Aristotle University School of Medicine, Hippokration Hospital, Thessaloniki, 54642, Greece. Hauptthemen laut MEDLINE: Antifungal Agents, Intensive Care Units, Pediatric, Invasive Fungal Infections, Drug Prescriptions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Spanish Ministry of Science and Innovation-Instituto de Salud Carlos III and Fondos FEDER, Spanish Ministry of Science and Innovation—Instituto de Salud Carlos III and Fondos FEDER.
Themen: Intensivpflege
Abstract (Originalsprache)
Background
Critically ill pediatric patients admitted to the pediatric intensive care unit (PICU) are highly vulnerable to infections, including invasive fungal diseases and antifungal agents are frequently prescribed. Little is known about antifungal usage in PICUs across Europe.
Methods
A multinational 3-month weekly point-prevalence study for measuring antifungal drug use was organized. Eigtheen PICUs (16 hospitals) in 10 countries in the European region participated. All patients hospitalized in the participating PICUs and receiving systemic antifungals were included. Information about ward demographics was collected once; weekly ward and patient data were collected prospectively for the 12-week study period and entered in REDCap database.
Results
Among 18 PICUs, 8 (44%) followed prophylactic practices for targeted group of patients, 7/18 (39%) had an antifungal stewardship program and the majority (16/18, 89%) had the capacity of biomarker utilization (16/16 galactomannan, 13/16 beta-D-glucan, and 9/16 pan-fungal PCR). One hundred one courses in equal number of patients were recorded; 14 for patients aged <3 month, 87 for patients ≥3 month. Malignancy was the most common underlying condition among patients aged ≥3 month (29%) followed by surgery/trauma (25%), whereas all patients <3 month had undergone a recent surgery. Indication for antifungal prescribing was prophylaxis in 38% and treatment in 62% [empirical (57%), preemptive (13%), and targeted (30%)]. Fluconazole was the most common agent both for prophylaxis and treatment, whereas liposomal amphotericin B was the most frequent agent for targeted treatment. The majority (63%) of patients on prophylaxis were oncology or transplant patients. Common reasons for empirical and targeted treatment were persistent fever/other signs of infections in high-risk patients (61%) and Candida infections (100%), respectively. For targeted treatment, the most frequent pathogens were Candida albicans (37%) and Candida parapsilosis (32%).
Conclusions
Most antifungal prescriptions across European PICUs were for treatment. Fluconazole was the most frequently prescribed antifungal. These surveillance data can guide antifungal stewardship strategies in PICUs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Unit, 3rd Department of Pediatrics, Aristotle University School of Medicine, Hippokration Hospital, Thessaloniki, 54642, Greece.
- Al Qassimi Women's and Children's Hospital, Sharjah, 61405, United Arab Emirates.
- Hospital 12 de Octubre, Madrid, 28041, Spain.
- Department of Pediatric Infectious Diseases, Faculty of Medicine, Erciyes University, Kayseri, 38039, Türkiye.
- Infectious Disease Unit, IRCCS, Bambino Gesù Children's Hospital, Rome, 00165, Italy.
- Paediatric Immunology, Department of Infectious Diseases and Allergy, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE2 4AA, United Kingdom.
ORCID-Profile: Marieke Emonts, Laura Ferreras-Antolin, Carlos D Grasa, Elena Rincón-López, Adilia Warris, Emmanuel Roilides
Förderung
- Spanish Ministry of Science and Innovation-Instituto de Salud Carlos III and Fondos FEDER
- Spanish Ministry of Science and Innovation—Instituto de Salud Carlos III and Fondos FEDER
Zitieren
APA
Chorafa, E., Iosifidis, E., Alkhaaldi, A. A., Arias, A., Cetin, B. S., De Luca, M., Emonts, M., Ferreras-Antolin, L., Ghimenton-Walters, E., Grasa, C. D., Groll, A. H., Herrera-Castillo, L., Lehrnbecher, T., Manzanares, A., Masjosthusmann, K., Melendo, S., Mendoza-Palomar, N., Paulus, S., Rincón-López, E., …, & Roilides, E. (2025). Antifungal Prescribing in European Pediatric Intensive Care Units: Results of a Multinational 3-Month Weekly Point-Prevalence Survey. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piaf081
Vancouver
Chorafa E, Iosifidis E, Alkhaaldi AA, Arias A, Cetin BS, De Luca M, et al. Antifungal Prescribing in European Pediatric Intensive Care Units: Results of a Multinational 3-Month Weekly Point-Prevalence Survey. Journal of the Pediatric Infectious Diseases Society. 2025. doi:10.1093/jpids/piaf081
BibTeX
@article{Chorafa2025,
author = {Chorafa, Elisavet and Iosifidis, Elias and Alkhaaldi, Aisha Abdalla and Arias, Ana and Cetin, Benhur Sirvan and De Luca, Maia and Emonts, Marieke and Ferreras-Antolin, Laura and Ghimenton-Walters, Elisabetta and Grasa, Carlos D and Groll, Andreas H and Herrera-Castillo, Laura and Lehrnbecher, Thomas and Manzanares, Angela and Masjosthusmann, Katja and Melendo, Susana and Mendoza-Palomar, Natalia and Paulus, Stéphane and Rincón-López, Elena and Romani, Lorenza and Sdougka, Maria and Solopova, Galina and Strenger, Volker and Tedford, Kara and Tzika, Christina and Warris, Adilia and Zsigmond, Borbala and Roilides, Emmanuel},
title = {Antifungal Prescribing in European Pediatric Intensive Care Units: Results of a Multinational 3-Month Weekly Point-Prevalence Survey},
journal = {Journal of the Pediatric Infectious Diseases Society},
year = {2025},
doi = {10.1093/jpids/piaf081}
}
EUVIMED